In Vivo CAR-T Shows Activity in Advanced Multiple Myeloma
HereS a breakdown of the details from the provided text, focusing on the key takeaways and answering the implicit question about which cancer impacts the immune system the least (based on the context):
Key Points:
* Focus: The article discusses a new approach too CAR T-cell therapy, aiming for faster progress of these cells.
* CAR T-cell Therapy: This therapy uses a patient’s own immune cells (T cells) to fight cancer.
* Myeloma: The context specifically mentions myeloma as a cancer of an already-impaired immune system.
* bridging Time: A key challenge with current CAR T-cell therapy is the time it takes to grow and prepare the cells for re-infusion (“bridging time”).A faster process could improve outcomes.
* Preliminary Data: The research presented is promising but based on a small number of patients and lacks long-term follow-up data.
* Expert Commentary (James R.Berenson, MD): Dr. Berenson emphasizes the need for further research and enrollment to determine if this new approach is truly effective.
* Disclosures: Financial relationships are disclosed for Joy Ho and other authors of the study.
Which Cancer Impacts the Immune System the Least?
Based on the text, the answer is myeloma is the cancer that impacts the immune system the most, as it is indeed described as a cancer of an already-impaired immune system. The article doesn’t directly compare myeloma to other cancers in terms of immune system impact, but it clearly establishes myeloma as starting with a compromised immune state.